These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27633882)

  • 1. Combined models for pre- and post-treatment longitudinal biomarker data: an application to CD4 counts in HIV-patients.
    Stirrup OT; Babiker AG; Copas AJ
    BMC Med Res Methodol; 2016 Sep; 16():121. PubMed ID: 27633882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion.
    Stirrup OT; Copas AJ; Phillips AN; Gill MJ; Geskus RB; Touloumi G; Young J; Bucher HC; Babiker AG;
    HIV Med; 2018 Mar; 19(3):184-194. PubMed ID: 29230953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Joint longitudinal data analysis in detecting determinants of CD4 cell count change and adherence to highly active antiretroviral therapy at Felege Hiwot Teaching and Specialized Hospital, North-west Ethiopia (Amhara Region).
    Seyoum A; Ndlovu P; Temesgen Z
    AIDS Res Ther; 2017 Mar; 14(1):14. PubMed ID: 28302125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining CD4 recovery and CD4: CD8 ratio restoration as an indicator for evaluating the outcome of continued antiretroviral therapy: an observational cohort study.
    Lee SS; Wong NS; Wong BCK; Wong KH; Chan KCW
    BMJ Open; 2017 Sep; 7(9):e016886. PubMed ID: 28918411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractional Brownian motion and multivariate-t models for longitudinal biomedical data, with application to CD4 counts in HIV-positive patients.
    Stirrup OT; Babiker AG; Carpenter JR; Copas AJ
    Stat Med; 2016 Apr; 35(9):1514-32. PubMed ID: 26555755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of quantile mixed-effects model in modeling CD4 count from HIV-infected patients in KwaZulu-Natal South Africa.
    Yirga AA; Melesse SF; Mwambi HG; Ayele DG
    BMC Infect Dis; 2022 Jan; 22(1):20. PubMed ID: 34983387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings.
    Mahajan AP; Hogan JW; Snyder B; Kumarasamy N; Mehta K; Solomon S; Carpenter CC; Mayer KH; Flanigan TP
    J Acquir Immune Defic Syndr; 2004 May; 36(1):567-75. PubMed ID: 15097299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
    Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
    Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of guidelines for initiation of highly active antiretroviral therapy in a longitudinal cohort of HIV-infected individuals.
    Ioannidis JP; O'Brien TR; Goedert JJ
    AIDS; 1998 Dec; 12(18):2417-23. PubMed ID: 9875579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How soon after HIV seroconversion is antiretroviral therapy initiated? The UK Register of HIV Seroconverters Steering Committee.
    AIDS; 1999 Jul; 13(10):1241-7. PubMed ID: 10416529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term CD4 cell count recovery among Thai naive HIV-infected patients initiating HAART at low CD4 cell count.
    Chaiwarith R; Salee P; Kotarathitithum W; Sirisanthana T; Supparatpinyo K
    Curr HIV Res; 2009 May; 7(3):340-5. PubMed ID: 19442132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model.
    Chu H; Gange SJ; Yamashita TE; Hoover DR; Chmiel JS; Margolick JB; Jacobson LP
    Am J Epidemiol; 2005 Oct; 162(8):787-97. PubMed ID: 16135508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMMUNOLOGICAL PROFILES IN HIV POSITIVE PATIENTS FOLLOWING HAART INITIATION IN KIGALI, RWANDA.
    Twizerimana AP; Mwatha J; Musabyimana JP; Kayigi E; Harelimana Jde D; Karanja SM; Mutesa L
    East Afr Med J; 2014 Aug; 91(8):261-6. PubMed ID: 26862650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.